Physician Underestimation of the Risk of Gastrointestinal Stromal Tumor Recurrence After Resection | Gastroenterology | JAMA Oncology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.129.82. Please contact the publisher to request reinstatement.
1.
Demetri  GD, von Mehren  M, Antonescu  CR,  et al.  NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.  J Natl Compr Canc Netw. 2010;8(suppl 2):S1-S41.PubMedGoogle Scholar
2.
Zhu  J, Yang  Y, Zhou  L, Jiang  M, Hou  M.  A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome.  BMC Cancer. 2010;10:199.PubMedGoogle ScholarCrossref
3.
DeMatteo  RP, Lewis  JJ, Leung  D, Mudan  SS, Woodruff  JM, Brennan  MF.  Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.  Ann Surg. 2000;231(1):51-58.PubMedGoogle ScholarCrossref
4.
Essat  M, Cooper  K.  Imatinib as adjuvant therapy for gastrointestinal stromal tumors: a systematic review.  Int J Cancer. 2011;128(9):2202-2214.PubMedGoogle ScholarCrossref
5.
Joensuu  H.  Gastrointestinal stromal tumor (GIST).  Ann Oncol. 2006;17(suppl 10):x280-x286.PubMedGoogle ScholarCrossref
6.
Joensuu  H, Vehtari  A, Riihimäki  J,  et al.  Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts.  Lancet Oncol. 2012;13(3):265-274.PubMedGoogle ScholarCrossref
7.
DeMatteo  RP, Ballman  KV, Antonescu  CR,  et al; American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team for the Alliance for Clinical Trials in Oncology.  Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial.  Ann Surg. 2013;258(3):422-429.PubMedGoogle ScholarCrossref
8.
Joensuu  H, Eriksson  M, Sundby Hall  K,  et al.  One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.  JAMA. 2012;307(12):1265-1272.PubMedGoogle ScholarCrossref
9.
von Mehren  M, Benjamin  RS, Bui  MM,  et al.  Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines.  J Natl Compr Canc Netw. 2012;10(8):951-960.PubMedGoogle Scholar
10.
Agaimy  A.  Gastrointestinal stromal tumors (GIST) from risk stratification systems to the new TNM proposal: more questions than answers? a review emphasizing the need for a standardized GIST reporting.  Int J Clin Exp Pathol. 2010;3(5):461-471.PubMedGoogle Scholar
11.
Fletcher  CD, Berman  JJ, Corless  C,  et al.  Diagnosis of gastrointestinal stromal tumors: a consensus approach.  Hum Pathol. 2002;33(5):459-465.PubMedGoogle ScholarCrossref
12.
Miettinen  M, Lasota  J.  Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis.  Arch Pathol Lab Med. 2006;130(10):1466-1478.PubMedGoogle Scholar
13.
Joensuu  H.  Risk stratification of patients diagnosed with gastrointestinal stromal tumor.  Hum Pathol. 2008;39(10):1411-1419.PubMedGoogle ScholarCrossref
14.
Gold  JS, Gönen  M, Gutiérrez  A,  et al.  Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis.  Lancet Oncol. 2009;10(11):1045-1052.PubMedGoogle ScholarCrossref
15.
Conley  AP, Sasane  M, Pelletier  CL,  et al.  Assessment and management of the risk of recurrence of resected gastrointestinal stromal tumors. ASCO Meeting Abstracts. January 27, 2014 2014;32(3 suppl):119.
16.
 Standards for the Classification of Federal Data on Race and Ethnicity. Office of Management and Budget website. https://www.whitehouse.gov/omb/fedreg_race-ethnicity. Accessed June 22, 2015.
17.
Lin  DY, Wei  LJ, Ying  Z.  Checking the Cox model with cumulative sums of martingale-based residuals.  Biometrika. 1993;80(3):557-572. doi:10.1093/biomet/80.3.557.Google ScholarCrossref
18.
American Society of Clinical Oncology.  The state of cancer care in America, 2014: a report by the American Society of Clinical Oncology.  J Oncol Pract. 2014;10(2):119-142.PubMedGoogle ScholarCrossref
19.
Forte  GJ, Hanley  A, Hagerty  K, Kurup  A, Neuss  MN, Mulvey  TM.  American Society of Clinical Oncology National Census of Oncology Practices: preliminary report.  J Oncol Pract. 2013;9(1):9-19.PubMedGoogle ScholarCrossref
Original Investigation
September 2015

Physician Underestimation of the Risk of Gastrointestinal Stromal Tumor Recurrence After Resection

Author Affiliations
  • 1Analysis Group Inc, Montreal, Quebec, Canada
  • 2Novartis Pharmaceuticals Corp, East Hanover, New Jersey
  • 3Department of Sarcoma Medical Oncology, MD Anderson Cancer Center, Houston, Texas
JAMA Oncol. 2015;1(6):797-805. doi:10.1001/jamaoncol.2015.2407
Abstract

Importance  Patients with resectable gastrointestinal stromal tumors (GISTs) might not receive the recommended duration of adjuvant therapy if their risk of recurrence is underestimated, which can have an impact on their recurrence-free survival (RFS).

Objective  To determine the extent of physician underestimation of risk of recurrence after complete primary GIST resection, the impact of underestimation on planned adjuvant treatment duration, and the association among high-risk patients of planned adjuvant treatment duration and RFS.

Design, Setting, and Participants  This was a retrospective observational medical record review reported by participating oncologists in 2013. US patients with complete primary GIST resection after 2010 were grouped as underestimated or not if their oncologists’ charted risk assessments were lower than assessments based on the Revised National Institutes of Health Consensus Criteria or not. Patients were followed by general community oncologists until death or the end of follow-up.

Main Outcomes and Measures  Fisher exact tests compared planned adjuvant treatment duration between groups. Cox proportional-hazards models estimated the impact of planned adjuvant treatment duration on RFS.

Results  A total of 109 oncologists reported information on 506 patients with GIST after primary resection (65.8% were high-risk and 8.7% were intermediate-risk). Physicians underestimated risk for 190 patients (37.5%); 30.1% of tumors with an intermediate-level mitotic count (6-10 per 50 high-powered fields) and an intermediate tumor size (6-10 cm) were correctly recognized as high-risk, as were 7.5% of nongastric tumors with an intermediate-level mitotic count and a tumor size of 2 to 5 cm. A smaller proportion of high-risk patients in the underestimated vs not-underestimated groups had at least 3 years of planned adjuvant therapy (36.1% vs 65.9%; P < .001). Planned adjuvant treatment of at least 3 years vs less than 3 years among high-risk patients conferred a lower hazard of recurrence and/or death (adjusted hazard ratio, 0.29; P < .001; 95% CI, 0.14-0.59).

Conclusions and Relevance  Overall, physicians tended to underestimate the risk of recurrence for many patients with GIST, especially for patients with tumors of intermediate size, intermediate-level mitotic count, and nongastric location, which had an impact on planned adjuvant therapy duration. Patients with at least 3 years of planned adjuvant treatment had longer RFS. Improved education on postresection risk assessment and risk reduction is needed.

×